Literature DB >> 19710463

Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice.

Marielle A Otten1, Tom W L Groeneveld, Roelof Flierman, Maria Pia Rastaldi, Leendert A Trouw, Maria C Faber-Krol, Annemieke Visser, Maria C Essers, Jill Claassens, J Sjef Verbeek, Cees van Kooten, Anja Roos, Mohamed R Daha.   

Abstract

To elucidate the mechanisms of glomerulonephritis, including Goodpasture's syndrome, mouse models are used that use heterologous Abs against the glomerular basement membrane (GBM) with or without preimmunization with foreign IgG from the same species. These studies have revealed the requirement of either FcgammaR or complement, depending on the experimental model used. In this study, we provide evidence that both FcgammaR and complement are obligatory for a full-blown inflammation in a novel attenuated passive model of anti-GBM disease. We demonstrate that administration of subnephritogenic doses of rabbit anti-GBM Abs followed by a fixed dose of mouse mAbs to rabbit IgG, allowing timing and dosing for the induction of glomerulonephritis, resulted in reproducible complement activation via the classical pathway of complement and albuminuria in wild-type mice. Because albuminuria was absent in FcR-gamma-chain(-/-) mice and reduced in C3(-/-) mice, a role for both FcgammaR and complement is postulated. Because C1q(-/-) and C4(-/-) mice lacking a functional classical and lectin pathway did develop albuminuria, we suggest involvement of the alternative pathway of complement. Anti-GBM glomerulonephritis occurs acutely following the administration of mouse anti-rabbit IgG, and proceeds in a chronic fashion dependent on both FcgammaR and complement. This novel attenuated model allows elucidating the relative contribution of different mediator systems of the immune system to the development of renal injury, and also provides a platform for the assessment of different treatment protocols and evaluation of drugs that ultimately may be beneficial for the treatment of anti-GBM mediated glomerulonephritides.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710463     DOI: 10.4049/jimmunol.0901301

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Novel therapy for anti-glomerular basement membrane disease with IgA nephropathy: A case report.

Authors:  Dechao Xu; Jianxiang Wu; Jun Wu; Chenggang Xu; Yuqiang Zhang; Changlin Mei; Xiang Gao
Journal:  Exp Ther Med       Date:  2016-03-11       Impact factor: 2.447

Review 2.  Goodpasture's disease: molecular architecture of the autoantigen provides clues to etiology and pathogenesis.

Authors:  Vadim Pedchenko; Roberto Vanacore; Billy Hudson
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-05       Impact factor: 2.894

3.  An unusual case of anti-glomerular basement membrane disease presenting with nephrotic syndrome.

Authors:  Chidi C Okafor; Rasheed A Balogun; David T Bourne; Turki O Alhussain; E M Abdel-Rahman
Journal:  Int Urol Nephrol       Date:  2010-11-18       Impact factor: 2.370

Review 4.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

5.  Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/reperfusion injury.

Authors:  Haekyung Lee; Danielle J Green; Lawrence Lai; Yunfang Joan Hou; Jens C Jensenius; David Liu; Cheolho Cheong; Chae Gyu Park; Ming Zhang
Journal:  Mol Immunol       Date:  2009-12-09       Impact factor: 4.407

6.  Proteolysis breaks tolerance toward intact α345(IV) collagen, eliciting novel anti-glomerular basement membrane autoantibodies specific for α345NC1 hexamers.

Authors:  Florina Olaru; Xu-Ping Wang; Wentian Luo; Linna Ge; Jeffrey H Miner; Sandra Kleinau; Xochiquetzal J Geiger; Andrew Wasiluk; Laurence Heidet; A Richard Kitching; Dorin-Bogdan Borza
Journal:  J Immunol       Date:  2013-01-09       Impact factor: 5.422

7.  Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease.

Authors:  Rui Ma; Zhao Cui; Yun-hua Liao; Ming-hui Zhao
Journal:  J Clin Immunol       Date:  2012-09-02       Impact factor: 8.317

8.  The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease.

Authors:  Rui Ma; Zhao Cui; Shui-Yi Hu; Xiao-Yu Jia; Rui Yang; Xin Zheng; Jie Ao; Gang Liu; Yun-Hua Liao; Ming-Hui Zhao
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

9.  Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease.

Authors:  Shui-Yi Hu; Xiao-Yu Jia; Xiao-Wei Yang; Feng Yu; Zhao Cui; Ming-Hui Zhao
Journal:  BMC Immunol       Date:  2013-09-21       Impact factor: 3.615

Review 10.  Vasculitides and the Complement System: a Comprehensive Review.

Authors:  Maria Sole Chimenti; Eleonora Ballanti; Paola Triggianese; Roberto Perricone
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.